Group 1 - The company expects to achieve an annual revenue of 351 million yuan for 2025, remaining stable compared to the previous year [1] - The net profit attributable to shareholders is projected to be -409 million yuan, with a net profit of -148 million yuan after excluding non-recurring gains and losses, also stable year-on-year [1] - The decline in performance is primarily due to the underperformance of the company's investment in Shenzhou Medical Technology Co., leading to an expected loss of approximately 260 million yuan from fair value changes of financial assets [1] Group 2 - The company aims to align with the "Healthy China" initiative and the "Three Medical Coordination" reform, focusing on the digitalization and informatization of the healthcare industry [2] - The core strategy revolves around the aggregation, circulation, and application of health big data, targeting areas such as comprehensive management of medical insurance funds and healthcare service innovation [2] - The company is actively exploring investment collaborations to support the "Healthy China" strategy with technical support and professional services [2]
国新健康发布2025年业绩预告 主营业务保持稳健